Pharmacoeconomic analysis of perioperative chemo-immunotherapy in resectable stage III non small cell lung cancer (NSCLC): Survival time cost-efficacy based on NADIM 2 trial.
Year: 2025
Type: article
Source: Journal of Clinical Oncology
Authors: Bartomeu Massuti, Ernest Nadal, Jose-Luis Gonzalez-Larriba, Alex Martinez-Marti, Reyes Bernabé, Joaquim Bosch-Barrera, Martín Lázaro, Virginia Calvo, Amelia Insa, Santiago Ponce Aix, Noemi Reguart, Javier De Castro, Rosario Garcia Campelo, Carlos Camps, Manuel Cobo, Santiago Viteri, Eider Azkona, Eva Pereira, Mariano Provencio, Spanish Lung Cancer Group (GECP/SLCG)
Institutions: Universitat de Miguel Hernández d'Elx, Institut Català d'Oncologia, Duran i Reynals Hospital, Hospital Clínico San Carlos, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Hospital Universitario Virgen del Rocío, Hospital Universitari de Girona Doctor Josep Trueta, University Hospital Complex Of Vigo, Hospital Universitario Puerta de Hierro Majadahonda, Hospital Clínico Universitario de Valencia, Hospital Universitario 12 De Octubre, Hospital Clínic de Barcelona, Hospital Universitario La Paz, Hospital General Universitario De Valencia, Instituto de Investigación Biomédica de Málaga, Hospital de Cruces
Language: English
Subfield: Economics and Econometrics
Domain: Social Sciences
Open Access status: closed
OpenAlex ID: W4410812347